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Salvianolate (SAL) is a prescribed medicine from the Chinese herb Danshen (Salvia miltiorrhiza Bunge). It
has been widely used in treatment of coronary and other diseases with signiﬁcant effects. The in vitro
antimicrobial activities of SAL against infectious pathogens were assayed and its combined effects on 10
clinical isolates of SCCmec III type methicillin-resistant Staphylococcus aureus (MRSA) with ten antibiotics
were evaluated. Susceptibility to each agent alone was tested using a broth microdilution method, and
the chequerboard and time-kill experiments were used for the combined activities. The results showed
MIC was 128e256 mg/L for SAL used alone against MRSA. Signiﬁcant synergies were observed for SAL/
Ampicillin (Fosfomycin, Erythromycin, Piperacillin-tazobactam or Clindamycin) combination against over
half of the isolates, with their MICs reduced by times of dilution (TOD) to 4e32 (FICIs 0.375e0.5),
respectively. SAL/AMP combination showed the best combined effect of synergy on bacteriostatic and
bactericidal activities, while SAL/AMK combination reversed the resistance of MRSA to AMK. The results
demonstrated that SAL enhanced widely the in vitro anti-MRSA efﬁcacy of the ten antibacterial agents,
which had potential for combinatory therapy of patients infected with MRSA and warrants further
investigations.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Since the clinical isolate of methicillin-resistant Staphylococcus
aureus (MRSA) was ﬁrst reported in 1961, its current incidence is
still high worldwide. MRSA could be amount to over 50% strains of
all S. aureus in clinical infected patients, leading to increased
morbidity and mortality, length of stay and healthcare burden (1,
2). MRSA is resistant not only to b-lactams, but also to macro-
lides, clindamycin, quinolones and other antibacterial agents. MRSA
has become one of the important pathogens in nosocomial pa-
tients, mostly causes infections of respiratory tract, burns, surgical
site and bloodstream. The elderly patients are one group of the
main risk individuals (3). MRSA infections often become the fatal
pathogeny among patients with multiple organ malfunctions orrmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).tumors. Although vancomycin is still one of the most effective anti-
MRSA agent, it has a lot of adverse effects such as hypotension,
phlebitis, nephrotoxicity, ototoxicity, hypersensitivity reactions, red
man syndrome, neutropenia, chills, fever and interstitial nephritis
(4). The emergence of decreased vancomycin susceptibility and
even resistant strains in MRSA has exhibited a signiﬁcant clinical
problem as well (5). Therefore, new treatment strategies to cope
with MRSA infections and to alleviate selection pressure of MRSA
on the current anti-MRSA agents are inevitably needed.
Salvianolate (SAL) is a prescribed medicine derived from
Danshen's principal active constituent Salvianolic acid B (6). It
contains mainly Magnesium salvianolic acid B (85%, Fig. 1) and
other phenolic acids (15%) (7, 8). Danshen is originated from the
well-known Chinese herb Salvia miltiorrhiza Bunge (Labiatae)
which has the function of promoting blood circulation (9, 10). Both
SAL and Danshen has been widely used in the treatment of car-
diovascular and cerebrovascular diseases (6, 10). A recent report
demonstrated that Salvianolic acid B could protect against acet-
aminophen hepatotoxicity (11). However, no detailed evaluation ofnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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Fig. 1. The schematic diagram of magnesium salvianolic acid B.
Table 1
MICs of SAL and the ten antibacterial agents against MRSA strains (mg/L, n ¼ 10).
Agenta Range MIC50 MIC90 MIC interpretive criteriab
S I R
AMP 16e128 64 64 0.25 e 0.5
CAZ 256e512 512 512 8 16 32
CFZ 64e512 256 512 8 16 32
CLI 128e1024 256 512 0.5 1e2 4
CPS 256e1024 256 1024 e e e
PTZ 32e256 128 256 8/4 e 16/4
ERY 256e4096 2048 2048 0.5 1e4 8
AMK 16e32 32 32 16 32 64
FOS 16e256 64 256 e e e
LEV 7.8e125 31.25 62.5 1 2 4
SAL 128e256 256 256 e e e
VAN 1 1 1 4 8e16 32
a SAL: Salvianolate; AMP: Ampicillin; CAZ: Ceftazidime; CFZ: Cefazolin; CPS:
Cefoperazone-sulbactam; PTZ: Piperacillin-tazobactam; AMK: Amikacin; CLI: Clin-
damycin; ERY: Erythromycin; FOS: Fosfomycin; LEV: Levoﬂoxacin; VAN:
Vancomycin.
b MIC Interpretive Criteria (2012 CLSI M100-S22); “S”: susceptible; “I”: interme-
diate; “R”: resistant.
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Therefore, we herein present the report which deals with in vitro
antibacterial and synergistic effects of SAL on conventional anti-
bacterial agents against clinical isolates of MRSA.
2. Materials and methods
2.1. Bacterial strains and culture media
MRSA strains (ten isolates with SCCmec III genotype) were
isolated and identiﬁed from the clinical sample of patients in
Kunming General Hospital as previous reports (12e14). ATCC
25923 was used as the control strain. Standard MuellereHinton
agar and broth (MHA and MHB, Tianhe Microbial Agents Co.,
Hangzhou, China) were used as bacterial culture media.
2.2. Antibacterial agents
SAL and ten antibacterial agents represented different conven-
tional types were purchased from the manufacturers, i.e. Salvia-
nolate (SAL (contains 85% magnesium salvianolic acid B),
Shanghai Greenvalley Pharmaceutical Co., Ltd, Shanghai, China),
and Ampicillin (AMP, North China Pharmaceutical Co., Ltd, Shi-
jiazhuang, China), Ceftazidime (CAZ, Baiyunshan Tianxin Pharma-
ceutical Co., Ltd, Guangzhou, China), Cefazolin (CFZ, Harbin
Pharmaceutical Co., Ltd, Harbin, China), Clindamycin (CLI, Lifeshine
Pharmaceutical Co., Ltd, Beijing, China), Cefoperazone-sulbactam,
Erythromycin, Fosfomycin and Piperacillin-tazobactam (CPS, ERY,
FOS and PTZ, Hunan Central South Kelun Pharmaceutical Co., Ltd,
Changsha, China). Amikacin (AMK, Jiangsu Wuzhong Pharmaceu-
tical Group Co., Ltd.); Levoﬂoxacin (LEV, Yangzhijiang Pharmaceu-
tical Co., Ltd, Taizhou, China). Vancomycin (VAN) (Eli Lilly Japan K.
K., Seishin Laboratories) was used as the positive control agent.
Cefoxitin disks were purchased from Tiantan biological products
Co., Ltd (Beijing, China).
2.3. Susceptibility of SAL and antibacterial agents alone against
MRSA
Susceptibility of each drug used alone against MRSA was
determined by standardized broth microdilution techniques with
inoculums of 5  105 CFU/mL according to CLSI guidelines and
incubated at 35 C for 24 h (15, 16). The testing solution was pre-
pared by dissolving SAL or the agents in sterile saline. Serial di-
lutions were made with the corresponding culture broth. The
minimum inhibitory concentration (MIC) and minimumbactericidal concentration (MBC) representing a drug's antibacte-
rial activity against MRSA isolates. All experiments were performed
in triplicate.
2.4. Synergy testing of SAL in combination with the antibacterial
agents against MRSA
Potential anti-MRSA synergy of SAL in combination with the ten
antibacterial agents against MRSA was measured by fractional
inhibitory concentration (FIC) indices (FICI) with chequerboard
methodandbytime-killingcurvesaspreviously reported (17,18). The
FICof thecombinationwascalculated throughdividing theMICof the
SAL/antibacterial agent combined by the MIC of SAL or the antibac-
terial agent alone, and the FICI was obtained by adding the FIC of SAL
and that of an antibacterial agent. The FICI resultswere interpreted as
follows: FICI 0.5, synergy; 0.5< FICI 1, additivity; and1< FICI 2,
indifference (or no effect) and FICI >2, antagonism (17). In the killing
curves, synergywas deﬁned as2 log10 CFU/mL increase in killing at
24hwith the combination in comparisonwith the killingby themost
active singledrug (△Log10 CFU/mLat24h, i.e.△LC24).Additivitywas
deﬁnedasa1e2 log10CFU/mL increase inkillwith thecombination in
comparison with the most active single agent. Indifference was
deﬁned as ±1 log10 CFU/mL killing or growth. Combinations that
resulted in>1 log10 CFU/mL bacterial growth in comparisonwith the
least active single agent were considered to represent antagonism
(18). All experiments were performed in triplicate.
3. Results
3.1. Effects of SAL used alone against MRSA
The MICs (mg/L) of Salvianolate (SAL, Fig. 1) and the ten clinical
antibacterial agents AMP, AMK, CAZ, CFZ, CLI, CPS, ERY, FOS, LEV
and PTZ used alone against 10 clinical MRSA isolates of SCCmec III
type are shown in Table 1. SAL showed MIC50 and MIC90 of both
256 mg/L (n ¼ 10). Meanwhile, SAL used alone showed similar
activity against standard Gram-positive S. aureus (methicillin-sus-
ceptible S. aureus, MSSA) by MIC/MBC at 128/256 mg/L.
3.2. Anti-MRSA potentiation of the agents by SAL
The combined anti-MRSA MICs of SAL with the ten antibacterial
agents are shown in Table 2. The potentiation effects could be
Table 3
Collected time-killing assay results of various combinations of SAL with antibiotics
at 24 h incubation against a clinical MRSA144 strain.
Combinationa Mascb △LC24(Int)c
SAL/AMP AMP 2.04 (Syn)
SAL/CAZ CAZ 1.73 (Add)
SAL/ERY ERY 1.49 (Add)
SAL/CLI SAL (¼CLI) 1.39 (Add)
SAL/AMK AMK 1.13 (Add)
SAL/FOS FOS 1.06 (Add)
SAL/LEV LEV 0.94 (Ind)
SAL/CPS CPS 0.70 (Ind)
SAL/PTZ PTZ 0.64 (Ind)
SAL/CFZ CFZ 0.59 (Ind)
a SAL: Salvianolate; AMP: Ampicillin; CAZ: Ceftazidime; CFZ: Cefazolin; CPS:
Cefoperazone-sulbactam; PTZ: Piperacillin-tazobactam; AMK: Amikacin; CLI: Clin-
damycin; ERY: Erythromycin; FOS: Fosfomycin; LEV: Levoﬂoxacin.
b Masc: most active single drug.
c △LC24: △Log10 CFU/mL at 24 h; Int: Interaction; Syn: synergy (△LC24  2);
Add: additivity (1 <△LC24 < 2); Ind: indifference (△LC24 ¼ ±1).
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been described previously (17). The results indicated synergistic
effects of SAL with the agents judged by FICIs obtained from the
chequerboard method, together with the times of dilution (TOD) of
the combined MICs. The bigger TOD of a combination, the more
times of MICs of an agents' pair would be reduced in the combi-
nation, and the FICI would become smaller as well. Hence, a smaller
FICI but bigger TOD means the more effective on MRSA by the
combined use of an antibacterial agent with SAL. It was found that
Both SAL and its combined agents showed various degree of
increased activities against MRSA strains in the combinations,
which led to different TOD of MICs from 4 to 32 (FICIs 0.375e0.5)
compared to those used alone against half of the isolates as MIC50
presented in Table 1 and values of 50% in Table 2. The best TOD was
32 in the combinations of SAL with ERY, with MIC reducing from
2048 (Table 1) to 64 mg/L (Table 2). All the ten combinations
showed 2e8 isolates of synergy or additive effect in the 10 MRSA
strains as presented in the right end sub-columns of Interactions in
Table 2. Table 3 shows results of the combined time-killing analysis
of SAL with the ten antibacterial agents. In addition, three typical
killing curves by combination of SAL with AMP, CLI and LEV at their
MIC level are exempliﬁed in Fig. 2. All combinations appeared as
not signiﬁcantly bactericidal interactions as compared to the
combined bacteriostatic effects (Tables 2 and 3, Fig. 2). Only the
combinations of SAL with AMP showed synergy and the ﬁve
combinations with AMK, CAZ, CLI, ERY and FOS showed only
additivity. The rest combinations showed indifference.Table 2
MICs (mg/L) and FIC indices (FICIs) of SAL in combination with ten antibacterial agents a
Combinationa Effectb Range 50%c
SAL/AMP FICI 0.25e0.75 0.375
MIC 8/8e128/32 32/16
TOD 32/8e4/2 8/4
SAL/FOS FICI 0.1e0.75 0.5
MIC 16/4e128/64 64/16
TOD 8/16e2/2 4/4
SAL/ERY FICI 0.25e0.75 0.5
MIC 32/64e64/1024 32/64
TOD 8/32e2/4 4/32
SAL/PTZ FICI 0.313e0.75 0.5
MIC 16/8e64/64 32/32
TOD 4/16e2/4 4/4
SAL/CLI FICI 0.313e1 0.5
MIC 32/16e128/256 64/32
TOD 8/16e2/2 4/8
SAL/CPS FICI 0.281e1 0.531
MIC 16/8e64/512 32/64
TOD 4/32e2/2 2/16
SAL/CFZ FICI 0.313e1 0.563
MIC 8/16e128/256 32/64
TOD 32/16e2/2 4/4
SAL/CAZ FICI 0.313e1 0.563
MIC 64/32e128/256 64/32
TOD 4/16e2/2 2/16
SAL/LEV FICI 0.313e1 0.75
MIC 8/1.953e64/31.25 32/15
TOD 16/4e2/2 4/2
SAL/AMK FICI 0.375e1 0.625
MIC 16/2e128/16 64/8
TOD 8/16e2/2 4/4
a SAL: Salvianolate; AMP: Ampicillin; CAZ: Ceftazidime; CFZ: Cefazolin; CPS: Cefopera
ERY: Erythromycin; FOS: Fosfomycin; LEV: Levoﬂoxacin.
b FICI: fractional inhibitory concentration index, FICIA combined with B ¼FICA þ FIC
dilution ¼ MICAlone/MICCombined, ranged from the maximum to the minimum. Add: Addi
c MRSA: methicillin resistant S. aureus; 50%: Values of inhibition against 50% of MRSA s
(also TOD and FICI) is presented as SAL to the left of “/” and an antibacterial agent to the
d n0: the number of strains showed the action.4. Discussion
In the present report, we performed in vitro assays the anti-
MRSA potentials of SAL used alone and synergistic interactions of
SAL in combination with conventionally used antibacterial agents
in clinic. It revealed a broad spectrum of synergy or additivity ef-
fects when SAL was combined with clinical agents of differentgainst MRSA strains (n ¼ 10).
90% Interaction (n0)d
Syn Add Ind
0.75 8 2 0
128/32
4/2
0.75 5 5 0
64/32
2/4
0.531 5 5 0
64/512
2/4
0.75 5 5 0
64/64
2/4
0.625 5 5 0
128/128
2/4
1 3 7 0
64/256
2/2
1 3 7 0
64/256
2/2
0.75 3 7 0
128/128
2/4
1 3 7 0
.625 64/31.25
2/2
1 2 8 0
128/16
2/2
zone-sulbactam; PTZ: Piperacillin-tazobactam; AMK: Amikacin; CLI: Clindamycin;
B ¼ [MICA (combined)/MICA (alone)] þ [MICB (combined)/MICB (alone)]; TOD: times of
tivity (0.5< FICI1); Ind: Indifference (1< FICI2); Syn: Synergy (FICI0.5).
trains; Values are expressed as those of SAL/antibacterial agents, i.e. the value of MIC
right of “/”.
Fig. 2. Selected time-killing curves of three combinations of SAL with AMP (A), CLI (B) and LEV (C) at 1  MIC and 24 h incubation against a clinical MRSA144 strain.
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agents showed positive interactions by various degrees.
However, SAL showed very weak activity against Gram-negative
clinical pathogens of Escherichia coli (ATCC25922 and ATCC35218)
and Pseudomonas aeruginosa (ATCC27853), and the fungus of
Candida albicans (ATCCY0109). All these pathogens showed MICs
2048 mg/L (data no shown).
SAL has been widely used for the treatment of cardiovascular
and cerebrovascular diseases (6). These effects of SAL, including
Salvianolic acid B and other Danshen's components and Danshen
itself are so far the predominant research topics in the previous
reports (6e11, 19). Apart from Danshen's extracts and a lipid-
soluble constituent Cryptotanshinone which have been studied of
the antibacterial activities (including (synergistic) activity against
MRSA), other active components in the extracts were not clariﬁed
(20e24). Neither SAL as well as Salvianolic acid B from Danshen
have been investigated against MRSA. Therefore, the systematic
evaluations of SAL antibacterial alone and its synergistic activities
with conventional antibacterial agents against MRSA are so far for
the ﬁrst time to our best knowledge.
It is interestingly noted that AMK with MIC50 of 32 mg/L alone
showed intermediate susceptible against the MRSA isolates by the
MIC Interpretive Criteria (25) (Table 1). However, its MIC50 reduced
to 8 mg/L when it was combined with SAL, so the resistance of
MRSA to AMK could be viewed as reversed in the combination of
SAL/AMK, which is a promising result of potentiation of the anti-
MRSA activity to be expected.
A previous report showed that the mechanism of synergy be-
tween epigallocatechin gallate (EGCG) and b-lactams such as AMP
against MRSA was attributed to interference with the integrity of
the cell wall through direct binding to peptidoglycan (26). Similarly,
another report also demonstrated that corilagin and tellimagrandin
I could remarkably potentiate the activity of b-lactams against
MRSA. The inactivation of PBPs, especially of PBP20 (PBP2a) and to
some extent suppression of b-lactamase activity by corilagin or
tellimagrandin I would make b-lactams restore their antibacterial
effect on MRSA (22, 27). As SAL, EGCG, corilagin and tellimagrandin
all contain multi-hydroxyl groups within their structures and can
be classiﬁed as polyphenols, the potentiation of b-lactams, espe-
cially of AMP by SAL might be ascribed to the same mechanisms.
For other b-lactams and antibacterial agents' types, mechanisms of
potentiation might be varied and remained to be studied.
As Table 1 shows and the previously reported, clinical MRSA
strains is a multidrug resistant bad bug (28, 29). It is continuing to
cause severe worldwide clinical problems. The critical shortage ofnew antibacterial agents makes global researchers pay great
attention to ﬁnd novel effective candidates and new treatment
ways (3, 30, 31). While suffering from cardiovascular and cerebro-
vascular diseases, the secondary respiratory infections by MRSA
often lead to death of elderly and immunocompromised patients.
The new effects of SALmay play an additional role in preventing the
patients fromMRSA infection. Given the known indications and our
new ﬁnding of SAL potentiation effects of antibacterial agents
against MRSA, it might be especially beneﬁcial to the patients with
both vascular diseases andMRSA infections. Nevertheless, potential
adverse factors cannot be ignored when SAL is used in combination
with an individual antibacterial agent, such as their mutual in-
ﬂuences on physicochemical property leading to incompatibility
and the inherent effect of SAL on heart whichmight be unnecessary
in some cases. Moreover, the number and types of pathogenic
species used for the evaluation remained to be enlarged, including
in depth animal and clinical investigations in the future.
In conclusion, we further demonstrated the vascular disease
effective Salvianolate (SAL) was also active on anti-MRSA potenti-
ation of multiple antibacterial agents, which may have the possi-
bility of combinatory therapy with antibacterial agents for the
patients of MRSA infection and warrants further pharmacological
investigations.
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